Literature DB >> 23929170

[Current strategies to minimize of blood loss during radical prostatectomy].

Christof M Strang1, Thomas Hachenberg.   

Abstract

Prostate cancer is a frequently diagnosed cancer in men with a high incidence. Despite enhancements of surgical techniques in prostatectomyperioperative blood loss is still the most frequent complication. Controlled hypotension (MAP 60-70mmHg) consisting of thoracal epidural anaesthesia und restrictive fluid management is a safe method to minimize blood loss. 25 degrees Trendelenburg position supports the multimodal treatment of controlled hypotension. Tranexamic acid is a safe drug to treat hyperfibrinolysis during prostate resection. © Georg Thieme Verlag Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23929170     DOI: 10.1055/s-0033-1352497

Source DB:  PubMed          Journal:  Anasthesiol Intensivmed Notfallmed Schmerzther        ISSN: 0939-2661            Impact factor:   0.698


  4 in total

1.  Risk factors of perioperative complications in patients undergoing radical retropubic prostatectomy: A ten-year experience.

Authors:  Xiao-Jun Liu; Liang Liu; Kun Chang; Ding-Wei Ye; Yong-Fa Zheng; Xu-Dong Yao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-06-06

2.  Intravenous versus topical tranexamic acid in primary total hip replacement: A meta-analysis.

Authors:  Pei Zhang; Yuan Liang; Pengtao Chen; Yongchao Fang; Jinshan He; Jingcheng Wang
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.889

Review 3.  Efficacy and safety of intravenous tranexamic acid administration in patients undergoing hip fracture surgery for hemostasis: A meta-analysis.

Authors:  Pei Zhang; Jinshan He; Yongchao Fang; Pengtao Chen; Yuan Liang; Jingcheng Wang
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

4.  Combined application versus topical and intravenous application of tranexamic acid following primary total hip arthroplasty: a meta-analysis.

Authors:  Pei Zhang; Yuan Liang; Pengtao Chen; Yongchao Fang; Jinshan He; Jingcheng Wang
Journal:  BMC Musculoskelet Disord       Date:  2017-02-21       Impact factor: 2.362

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.